摘要
目的:探讨阿托伐他汀联合曲美他嗪治疗冠心病的疗效及药效途径。方法:将80例冠心病患者随机分为观察组和对照组,两组均以常规治疗为基础,对照组采用阿托伐他汀,观察组在对照组基础上加用曲美他嗪,比较两组治疗前后的血脂、心功能、心绞痛的发作情况以及不良反应。结果:两组患者治疗前在心功能、心绞痛发作次数和发作持续时间方面均无统计学意义(P>0.05)。观察组治疗后的TC、TG、LDL-C、HDL-C、LVEDD、LVPW、LVEF、心绞痛发作次数和持续时间与对照组相比,差异显著(P<0.05)。不良反应两组比较无显著差异(P>0.05)。结论:阿托伐他汀联合曲美他嗪治疗冠心病疗效较好,可通过降低血脂水平,增强心功能,降低心绞痛发作,安全有效。
Objective ：To evaluate the joint atorvastatin trimetazidine treatment the curative effect of coronary heart disease （CHD） and effective way .Methods ：80 patients with coronary heart disease were randomly divided into observation group and control group ,both groups on the basis of conventional treatment ,control group adopts trimetazidine ,observation group in the control group with atorvastatin ,on the basis of comparing the two groups before and after treatment the blood lipids ,heart function ,the outbreak of angina pectoris and adverse reactions .Results ：Two groups of patients before treatment in heart function and attack frequency of angina pectoris and onset duration had no statistical significance （P 〉 0 .05） .Observation group after treatment of TC ,TG ,LDL , HDL - C ,LVEDD ,LVPW ,LVEF ,attack frequency of angina pectoris and duration compared with control group , the difference was statistically significant （P〉 0 .05） .Two groups of adverse reaction of no statistical significance （P〉0 .05） .Conclusion ：Atorvastatin with trimetazidine therapy of coronary heart disease curative effect is better , but by lowering lipid levels ,levels increased significantly in patients with cardiac function ,reduce heart attacks ,and less adverse reactions ,worthy of promotion .
出处
《陕西医学杂志》
CAS
2016年第12期1669-1670,共2页
Shaanxi Medical Journal
